BioNTech SE (NASDAQ:BNTX) Stake Reduced by Price T Rowe Associates Inc. MD

Price T Rowe Associates Inc. MD cut its stake in shares of BioNTech SE (NASDAQ:BNTX - Free Report) by 1.6% during the 4th quarter, according to its most recent filing with the SEC. The institutional investor owned 313,789 shares of the company's stock after selling 5,080 shares during the period. Price T Rowe Associates Inc. MD owned approximately 0.13% of BioNTech worth $35,757,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also recently bought and sold shares of the stock. Jones Financial Companies Lllp lifted its position in shares of BioNTech by 110.3% during the fourth quarter. Jones Financial Companies Lllp now owns 469 shares of the company's stock worth $53,000 after purchasing an additional 246 shares in the last quarter. Quintet Private Bank Europe S.A. lifted its holdings in BioNTech by 823.5% in the 4th quarter. Quintet Private Bank Europe S.A. now owns 785 shares of the company's stock worth $88,000 after buying an additional 700 shares in the last quarter. Allianz SE purchased a new position in BioNTech in the 4th quarter valued at about $90,000. GAMMA Investing LLC grew its stake in shares of BioNTech by 48.2% during the fourth quarter. GAMMA Investing LLC now owns 923 shares of the company's stock valued at $105,000 after acquiring an additional 300 shares in the last quarter. Finally, Generali Investments CEE investicni spolecnost a.s. purchased a new stake in shares of BioNTech during the fourth quarter worth about $137,000. Hedge funds and other institutional investors own 15.52% of the company's stock.

Analysts Set New Price Targets

BNTX has been the topic of several analyst reports. Truist Financial assumed coverage on BioNTech in a report on Friday, January 10th. They set a "buy" rating and a $172.00 price objective on the stock. BMO Capital Markets upped their price target on shares of BioNTech from $130.00 to $143.00 and gave the company an "outperform" rating in a report on Tuesday, March 11th. Canaccord Genuity Group reissued a "buy" rating and set a $171.44 price objective on shares of BioNTech in a report on Tuesday, March 11th. Citigroup initiated coverage on shares of BioNTech in a research note on Thursday, March 13th. They issued a "buy" rating and a $145.00 target price on the stock. Finally, HC Wainwright decreased their price target on BioNTech from $150.00 to $145.00 and set a "buy" rating for the company in a research note on Tuesday, April 1st. Three analysts have rated the stock with a hold rating, fourteen have issued a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat, the stock has a consensus rating of "Moderate Buy" and an average price target of $143.44.

BioNTech Stock Performance

Shares of NASDAQ:BNTX traded up $2.51 during trading hours on Friday, hitting $104.94. The stock had a trading volume of 729,399 shares, compared to its average volume of 913,865. The stock's fifty day simple moving average is $100.41 and its 200 day simple moving average is $110.08. The firm has a market capitalization of $25.18 billion, a price-to-earnings ratio of -49.97 and a beta of 1.07. The company has a debt-to-equity ratio of 0.01, a quick ratio of 7.21 and a current ratio of 7.33. BioNTech SE has a 1-year low of $76.53 and a 1-year high of $131.49.

BioNTech (NASDAQ:BNTX - Get Free Report) last announced its earnings results on Monday, March 10th. The company reported $1.08 earnings per share for the quarter, beating the consensus estimate of $0.38 by $0.70. The firm had revenue of $1.19 billion for the quarter, compared to the consensus estimate of $1.24 billion. BioNTech had a negative return on equity of 2.35% and a negative net margin of 15.16%. The firm's revenue for the quarter was down 19.5% on a year-over-year basis. During the same quarter in the previous year, the business earned $1.90 EPS. Sell-side analysts anticipate that BioNTech SE will post -3.88 earnings per share for the current fiscal year.

About BioNTech

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer.